NO20021357L - Amino-substituerte pyrazolo[1,5-a]-1,5-pyrimidiner og pyrazolo[1,5-a]-1,3,5-triaziner - Google Patents

Amino-substituerte pyrazolo[1,5-a]-1,5-pyrimidiner og pyrazolo[1,5-a]-1,3,5-triaziner

Info

Publication number: NO20021357L
Authority: NO; Norway
Prior art keywords: compounds; pyrazolo; disorders; triazines; pyrimidines
Prior art date: 1999-09-30

Application number

NO20021357A

Other languages

English (en)

Other versions

NO20021357D0 (no

Inventor

James W Darrow

Stephane De Lombaert

Charles Blum

Jennifer Tran

Mark Giangiordano

David Andrew Griffith

Philip Albert Carpino

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-30

Filing date

2002-03-19

Publication date

2002-05-23

2002-03-19 Application filed by Pfizer filed Critical Pfizer

2002-03-19 Publication of NO20021357D0 publication Critical patent/NO20021357D0/no

2002-05-23 Publication of NO20021357L publication Critical patent/NO20021357L/no

Links

125000003277 amino group Chemical group 0.000 title 1
JUXWUYWPUDKPSD-UHFFFAOYSA-N pyrazolo[1,5-a][1,3,5]triazine Chemical class N1=CN=CN2N=CC=C21 JUXWUYWPUDKPSD-UHFFFAOYSA-N 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 5
102000005962 receptors Human genes 0.000 abstract 4
108020003175 receptors Proteins 0.000 abstract 4
101150027439 NPY1 gene Proteins 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
208000035475 disorder Diseases 0.000 abstract 2
230000004807 localization Effects 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
208000030814 Eating disease Diseases 0.000 abstract 1
208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
238000003556 assay Methods 0.000 abstract 1
208000015114 central nervous system disease Diseases 0.000 abstract 1
235000014632 disordered eating Nutrition 0.000 abstract 1
208000030159 metabolic disease Diseases 0.000 abstract 1
230000002093 peripheral effect Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
239000000523 sample Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/5755—Neuropeptide Y
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Endocrinology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Anesthesiology (AREA)
Otolaryngology (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Investigating Or Analysing Biological Materials (AREA)

NO20021357A 1999-09-30 2002-03-19 Amino-substituerte pyrazolo[1,5-a]-1,5-pyrimidiner og pyrazolo[1,5-a]-1,3,5-triaziner NO20021357L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US15686899P	1999-09-30	1999-09-30
PCT/US2000/026885 WO2001023388A2 (en)	1999-09-30	2000-09-29	AMINO SUBSTITUTED PYRAZOLO[1,5,-a]-1,5-PYRIMIDINES AND PYRAZOLO[1,5-a]-1,3,5-TRIAZINES

Publications (2)

Publication Number	Publication Date
NO20021357D0 NO20021357D0 (no)	2002-03-19
NO20021357L true NO20021357L (no)	2002-05-23

Family

ID=22561433

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20021357A NO20021357L (no)	1999-09-30	2002-03-19	Amino-substituerte pyrazolo[1,5-a]-1,5-pyrimidiner og pyrazolo[1,5-a]-1,3,5-triaziner

Country Status (21)

Country	Link
US (1)	US6476038B1 (no)
EP (1)	EP1218381B1 (no)
JP (2)	JP2003510326A (no)
KR (1)	KR20020047201A (no)
CN (1)	CN1377355A (no)
AT (1)	ATE347553T1 (no)
AU (1)	AU7737900A (no)
BG (1)	BG106507A (no)
CA (1)	CA2379633C (no)
CZ (1)	CZ20021089A3 (no)
DE (1)	DE60032249T2 (no)
EA (1)	EA200200421A1 (no)
ES (1)	ES2277855T3 (no)
HU (1)	HUP0203131A3 (no)
IL (1)	IL148904A0 (no)
NO (1)	NO20021357L (no)
OA (1)	OA12049A (no)
PL (1)	PL354982A1 (no)
WO (1)	WO2001023388A2 (no)
YU (1)	YU23602A (no)
ZA (1)	ZA200202517B (no)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6472528B1 (en) *	1999-08-10	2002-10-29	Neurocrine Biosciences, Inc.	Synthesis of substituted pyrazolopyrimidines
PL354675A1 (en)	1999-09-30	2004-02-09	Neurogen Corporation	Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines
ATE302203T1 (de)	2002-03-07	2005-09-15	Smithkline Beecham Corp	Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
US7105526B2 (en)	2002-06-28	2006-09-12	Banyu Pharmaceuticals Co., Ltd.	Benzimidazole derivatives
FR2842809A1 (fr) *	2002-07-26	2004-01-30	Greenpharma Sas	NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
US7196078B2 (en)	2002-09-04	2007-03-27	Schering Corpoartion	Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
RS20050532A (sr)	2003-01-14	2007-12-31	Arena Pharmaceuticals Inc.,	Derivati 1,2,3-trisupstituisanog arila i heteroarila kao modulatori metabolizma za profilaksu i tretman poremećaja povezanih sa njim, kao što su dijebetes i hiperglikemija
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
US7329658B2 (en) *	2003-02-06	2008-02-12	Pfizer Inc	Cannabinoid receptor ligands and uses thereof
US7176210B2 (en) *	2003-02-10	2007-02-13	Pfizer Inc.	Cannabinoid receptor ligands and uses thereof
KR100824193B1 (ko)	2003-04-29	2008-04-21	화이자 인코포레이티드	고혈압 치료에 유용한5,7-디아미노피라졸로[4,3-ｄ]피리미딘
AR045047A1 (es)	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
KR20060056944A (ko)	2003-07-14	2006-05-25	아레나 파마슈티칼스, 인크.	대사 조절제로서 융합된 아릴 및 헤테로아릴 유도체 및이에 관련된 장애의 예방 또는 치료
WO2005028438A1 (ja)	2003-09-22	2005-03-31	Banyu Pharmaceutical Co., Ltd.	新規ピペリジン誘導体
US7208596B2 (en)	2003-11-25	2007-04-24	Bristol-Myers Squibb Pharma Company	Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
US7153961B2 (en)	2003-11-25	2006-12-26	Bristol-Myers Squibb Pharma Co.	Salt and crystalline form thereof of a corticotropin releasing factor receptor antagonist
US20070293511A1 (en) *	2003-12-22	2007-12-20	Sb Pharmco Puerto Rico Inc. And Neurocrine Biosciences, Inc., A Corporation	Crf Receptor Antagonists and Methods
JP4926720B2 (ja) *	2003-12-22	2012-05-09	スミスクラインビーチャム（コーク）リミテッド	Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法
US20080125403A1 (en)	2004-04-02	2008-05-29	Merck & Co., Inc.	Method of Treating Men with Metabolic and Anthropometric Disorders
GB0519957D0 (en)	2005-09-30	2005-11-09	Sb Pharmco Inc	Chemical compound
DK1814590T4 (da)	2004-11-01	2014-02-24	Amylin Pharmaceuticals Llc	Behandling af obesitet og beslægtede sygdomme.
CN101119998A (zh)	2004-12-21	2008-02-06	先灵公司	吡唑并[1,5－A]嘧啶腺苷A2a受体拮抗剂
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
EP1892241B1 (en)	2005-05-30	2016-03-30	Msd K.K.	Novel piperidine derivative
US7968105B2 (en)	2005-06-23	2011-06-28	Statens Serum Institut	Tuberculosis vaccines comprising antigens expressed during the latent infection phase
EP1916239A4 (en)	2005-08-10	2009-10-21	Banyu Pharma Co Ltd	PYRIDOLVERBINDUNG
EP2330125A3 (en)	2005-08-11	2012-12-12	Amylin Pharmaceuticals, Inc.	Hybrid polypeptides with selectable properties
EP1922336B1 (en)	2005-08-11	2012-11-21	Amylin Pharmaceuticals, LLC	Hybrid polypeptides with selectable properties
US7875633B2 (en)	2005-08-24	2011-01-25	Banyu Pharmaceutical Co., Ltd.	Phenylpyridone derivative
WO2007029847A1 (ja)	2005-09-07	2007-03-15	Banyu Pharmaceutical Co., Ltd.	二環性芳香族置換ピリドン誘導体
KR20080048502A (ko)	2005-09-29	2008-06-02	머크 앤드 캄파니 인코포레이티드	멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
RU2008119687A (ru)	2005-10-21	2009-11-27	Новартис АГ (CH)	Комбинации органических соединений
AU2006307046A1 (en)	2005-10-27	2007-05-03	Msd K.K.	Novel benzoxathiin derivative
RU2428423C2 (ru)	2005-11-10	2011-09-10	Баниу Фармасьютикал Ко., Лтд.	Азазамещенные спиропроизводные
KR101088239B1 (ko)	2006-09-20	2011-11-30	일라이 릴리 앤드 캄파니	Ｃｒｆ１ 수용체 길항제로서의 티아졸 피라졸로피리미딘
MX2009003098A (es)	2006-09-20	2009-04-01	Lilly Co Eli	Compuestos de tiofen pirazolopirimidina.
AU2007300627B2 (en)	2006-09-22	2012-02-16	Merck Sharp & Dohme Corp.	Method of treatment using fatty acid synthesis inhibitors
EP2072519A4 (en)	2006-09-28	2009-10-21	Banyu Pharma Co Ltd	DIARYLKETIMINDERIVAT
AU2008233662B2 (en)	2007-04-02	2012-08-23	Msd K.K.	Indoledione derivative
WO2008151257A2 (en)	2007-06-04	2008-12-11	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20120029204A1 (en) *	2007-06-07	2012-02-02	Schering Corporation	Synthesis of substituted-3-aminopyrazoles
AU2009220605A1 (en)	2008-03-06	2009-09-11	Msd K.K.	Alkylaminopyridine derivative
CA2717384A1 (en)	2008-03-28	2009-10-01	Banyu Pharmaceutical Co., Ltd.	Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
ES2627848T3 (es)	2008-06-04	2017-07-31	Synergy Pharmaceuticals Inc.	Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009261248A1 (en)	2008-06-19	2009-12-23	Banyu Pharmaceutical Co., Ltd.	Spirodiamine-diarylketoxime derivative
US20100015171A1 (en)	2008-07-15	2010-01-21	Statens Serum Institute	Vaccines comprising tb 10.4
ES2624828T3 (es)	2008-07-16	2017-07-17	Synergy Pharmaceuticals Inc.	Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
US20110124674A1 (en)	2008-07-30	2011-05-26	Hiroyuki Kishino	5/5-or 5/6-membered condensed ring cycloalkylamine derivative
US8410284B2 (en)	2008-10-22	2013-04-02	Merck Sharp & Dohme Corp	Cyclic benzimidazole derivatives useful as anti-diabetic agents
MX2011004551A (es)	2008-10-30	2011-05-25	Merck Sharp & Dohme	Antagonistas del receptor de orexina de isonicotinamida.
WO2010051206A1 (en)	2008-10-31	2010-05-06	Merck Sharp & Dohme Corp.	Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20110245209A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Pyridopyrimidine derivatives and methods of use thereof
US20110243940A1 (en)	2008-12-16	2011-10-06	Schering Corporation	Bicyclic pyranone derivatives and methods of use thereof
JP2013520502A (ja)	2010-02-25	2013-06-06	メルク・シャープ・エンド・ドーム・コーポレイション	有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
CN103221410B (zh)	2010-09-22	2017-09-15	艾尼纳制药公司	Gpr119受体调节剂和对与其相关的障碍的治疗
CA2826649C (en)	2011-02-25	2016-07-26	Merck Sharp & Dohme Corp.	Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
AR088352A1 (es)	2011-10-19	2014-05-28	Merck Sharp & Dohme	Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
US20140045746A1 (en)	2012-08-02	2014-02-13	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
EP2920181B1 (en)	2012-11-16	2019-01-09	University Health Network	Pyrazolopyrimidine compounds
JP2016516004A (ja)	2013-02-22	2016-06-02	メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋＳｈａｒｐ＆ＤｏｈｍｅＣｏｒｐ．	抗糖尿病二環式化合物
WO2014139388A1 (en)	2013-03-14	2014-09-18	Merck Sharp & Dohme Corp.	Novel indole derivatives useful as anti-diabetic agents
US9708367B2 (en)	2013-03-15	2017-07-18	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase and their uses
EP2968439A2 (en)	2013-03-15	2016-01-20	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
PL3004138T3 (pl)	2013-06-05	2024-07-29	Bausch Health Ireland Limited	Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie
WO2015051496A1 (en)	2013-10-08	2015-04-16	Merck Sharp & Dohme Corp.	Antidiabetic tricyclic compounds
BR112017003745A2 (pt)	2014-08-29	2017-12-05	Tes Pharma S R L	inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
CA3002540C (en)	2015-01-06	2023-11-07	Arena Pharmaceuticals, Inc.	Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
JP6838744B2 (ja)	2015-06-22	2021-03-03	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１Ｐ１レセプター関連障害における使用のための（Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸（化合物１）の結晶性Ｌ−アルギニン塩
UA125852C2 (uk)	2016-08-31	2022-06-22	Ле Лаборатуар Сервьє	Інгібітори клітинних метаболічних процесів
AU2017342083A1 (en)	2016-10-14	2019-04-11	Tes Pharma S.R.L.	Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018106518A1 (en)	2016-12-06	2018-06-14	Merck Sharp & Dohme Corp.	Antidiabetic heterocyclic compounds
WO2018118670A1 (en)	2016-12-20	2018-06-28	Merck Sharp & Dohme Corp.	Antidiabetic spirochroman compounds
CN110520124A (zh)	2017-02-16	2019-11-29	艾尼纳制药公司	用于治疗原发性胆汁性胆管炎的化合物和方法
BR112020002967A2 (pt)	2017-08-14	2020-08-11	Spruce Biosciences, Inc.	antagonistas de receptor de fator de liberação de corticotropina
ES3042162T3 (en) *	2018-04-10	2025-11-18	Bayer Ag	Method for the preparation of 2.6-dialkylphenyl acetic acids
MX2020011344A (es)	2018-04-27	2021-02-09	Spruce Biosciences Inc	Métodos para tratar tumores en reposo suprarrenales testiculares y de ovarios.
JP7397011B2 (ja)	2018-06-06	2023-12-12	アリーナファーマシューティカルズ，インコーポレイテッド	Ｓ１ｐ１受容体に関連する状態を治療する方法
KR20250174699A (ko)	2018-10-30	2025-12-12	크로노스 바이오, 인코포레이티드	Cdk9 활성을 조절하기 위한 화합물, 조성물 및 방법
EP3883930A1 (en)	2018-11-20	2021-09-29	Tes Pharma S.r.l.	Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2020167701A1 (en)	2019-02-13	2020-08-20	Merck Sharp & Dohme Corp.	Pyrrolidine orexin receptor agonists
US11098029B2 (en)	2019-02-13	2021-08-24	Merck Sharp & Dohme Corp.	5-alkyl pyrrolidine orexin receptor agonists
EP4010314B1 (en)	2019-08-08	2024-02-28	Merck Sharp & Dohme LLC	Heteroaryl pyrrolidine and piperidine orexin receptor agonists
JP2023537598A (ja)	2020-08-12	2023-09-04	スプルースバイオサイエンシーズ，インク．	多嚢胞性卵巣症候群を処置するための方法および組成物
US20230365533A1 (en)	2020-08-18	2023-11-16	Merck Sharp & Dohme Llc	Bicycloheptane pyrrolidine orexin receptor agonists
US11708372B2 (en)	2021-11-19	2023-07-25	Spruce Biosciences, Inc.	Crystalline composition of tildacerfont and methods of use and preparation thereof
CN115304607B (zh) *	2022-07-06	2023-06-27	华南农业大学	吡唑并嘧啶衍生物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU747708B2 (en)	1996-07-24	2002-05-23	Du Pont Pharmaceuticals Company	Azolo triazines and pyrimidines
WO1999007703A1 (en) *	1997-08-05	1999-02-18	Pfizer Products Inc.	4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS
US6187777B1 (en) *	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases

2000
- 2000-09-29 YU YU23602A patent/YU23602A/sh unknown
- 2000-09-29 OA OA1200200088A patent/OA12049A/en unknown
- 2000-09-29 EP EP00967132A patent/EP1218381B1/en not_active Expired - Lifetime
- 2000-09-29 ES ES00967132T patent/ES2277855T3/es not_active Expired - Lifetime
- 2000-09-29 EA EA200200421A patent/EA200200421A1/ru unknown
- 2000-09-29 CZ CZ20021089A patent/CZ20021089A3/cs unknown
- 2000-09-29 DE DE60032249T patent/DE60032249T2/de not_active Expired - Fee Related
- 2000-09-29 CN CN00813627A patent/CN1377355A/zh active Pending
- 2000-09-29 PL PL00354982A patent/PL354982A1/xx not_active Application Discontinuation
- 2000-09-29 AT AT00967132T patent/ATE347553T1/de not_active IP Right Cessation
- 2000-09-29 IL IL14890400A patent/IL148904A0/xx unknown
- 2000-09-29 CA CA002379633A patent/CA2379633C/en not_active Expired - Fee Related
- 2000-09-29 AU AU77379/00A patent/AU7737900A/en not_active Abandoned
- 2000-09-29 HU HU0203131A patent/HUP0203131A3/hu unknown
- 2000-09-29 US US09/676,972 patent/US6476038B1/en not_active Expired - Fee Related
- 2000-09-29 KR KR1020027004178A patent/KR20020047201A/ko not_active Ceased
- 2000-09-29 WO PCT/US2000/026885 patent/WO2001023388A2/en not_active Ceased
- 2000-09-29 JP JP2001526540A patent/JP2003510326A/ja not_active Ceased
2002
- 2002-03-11 BG BG106507A patent/BG106507A/xx unknown
- 2002-03-19 NO NO20021357A patent/NO20021357L/no not_active Application Discontinuation
- 2002-03-28 ZA ZA200202517A patent/ZA200202517B/xx unknown
2006
- 2006-09-06 JP JP2006241067A patent/JP2007077144A/ja active Pending

Also Published As

Publication number	Publication date
WO2001023388A2 (en)	2001-04-05
KR20020047201A (ko)	2002-06-21
YU23602A (sh)	2004-09-03
US6476038B1 (en)	2002-11-05
JP2007077144A (ja)	2007-03-29
EP1218381B1 (en)	2006-12-06
EP1218381A2 (en)	2002-07-03
CZ20021089A3 (cs)	2002-11-13
EA200200421A1 (ru)	2002-10-31
JP2003510326A (ja)	2003-03-18
ZA200202517B (en)	2003-05-28
ATE347553T1 (de)	2006-12-15
DE60032249D1 (de)	2007-01-18
CA2379633A1 (en)	2001-04-05
PL354982A1 (en)	2004-03-22
OA12049A (en)	2006-05-02
DE60032249T2 (de)	2007-07-19
CA2379633C (en)	2006-06-20
ES2277855T3 (es)	2007-08-01
HUP0203131A2 (hu)	2003-01-28
BG106507A (en)	2002-12-29
NO20021357D0 (no)	2002-03-19
HUP0203131A3 (en)	2004-06-28
CN1377355A (zh)	2002-10-30
WO2001023388A3 (en)	2001-10-18
IL148904A0 (en)	2002-09-12
AU7737900A (en)	2001-04-30

Legal Events

Date	Code	Title	Description
2005-06-20	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20021357D0 (no)	2002-03-19	Amino-substituerte pyrazolo[1,5-a]-1,5-pyrimidiner og pyrazolo[1,5-a]-1,3,5-triaziner
BG106506A (en)	2002-12-29	ALKYLENE DIAMINE-SUBSTITUTED PYRAZOLO[1,5,-a)-1,5-PYRIMIDINES AND PARAZOLO[1,5-a)-1,3,5-TRIAZINES
IL150085A0 (en)	2002-12-01	New-p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases
TR199801594A2 (xx)	1999-03-22	CCR-3 resept�r antagonistleri.
MY118163A (en)	2004-09-30	Aryl fused azapolycyclic compounds
TR200101398T2 (tr)	2001-09-21	Pirolidin türevleri-CCR-3 reseptörü antagonistleri.
WO2002076946A3 (en)	2002-12-27	Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain.
BG101715A (bg)	1998-02-27	Тетрациклени спиросъединения,метод за тяхното получаване и приложението им като 5нт долу 1d рецепторни антагонисти
MY122392A (en)	2006-04-29	Adamantane derivatives of use of p2x7 receptor antagonists, a process for their preparation, pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions
HUP0302793A3 (en)	2006-01-30	N-substituted aniline derivatives useful as phosphodiesterase 4 inhibitors, pharmaceutical compositions containing them and process for their preparations
JO2359B1 (en)	2006-12-12	Benzathene derivatives as agents for modulation of GABA A receptor
BG108427A (bg)	2005-01-31	2,5-диарилпиразини, 2,5-диарилпиридини и 2,5-диарилпиримидини като модулатори на crf1 рецептори
ZA200110540B (en)	2003-03-24	Novel diphenyl-piperidine derivate.
WO1996023769A3 (en)	1996-10-24	Heterocyclic compounds possessing 5ht2c receptor antagonist activity
ATE205480T1 (de)	2001-09-15	2,5-dioxo-2,5-dihydro-1h-benz(b)azepine als nmda rezeptor antagonisten
WO2002006242A3 (en)	2002-07-18	5-substituted 2-aryl-4-pyrimidinones
MY133474A (en)	2007-11-30	Aryl fused azapolycyclic compounds
WO2002011732A8 (en)	2002-06-20	Novel bicyclic and tricyclic pyrrolidine derivatives as gnrh antagonists
PT1673354E (pt)	2009-07-14	Arilindenopiridinas e arilindenopirimidinas e sua utilização como antagonistas do receptor da adenosina a2a
IL145645A0 (en)	2002-06-30	N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
GR3032950T3 (en)	2000-07-31	Substituted fused and bridged bicyclic compounds as therapeutic agents